Bicycle Therapeutics   Report issue

For profit Phase 2
Founded: Cambridge United Kingdom (2009)

Organization Overview

First Clinical Trial
2019
NCT04180371
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Bicycle Tx Limited | BicycleTx Limited

Active Ingredients

Drugs in Phase 2 Trials (4)

bt5528 (1 trial)

bt7480 (1 trial)

bt8009 (1 trial)

nivolumab (opdivo) (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Esophageal Neoplasms (Phase 2)

Neoplasms (Phase 2)

Ovarian Neoplasms (Phase 2)

Pancreatic Neoplasms (Phase 2)

Stomach Neoplasms (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 3
  • # of Trial APIs: 4